Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Innovation Stock A fund, which has shown a recent decline in net value but positive returns over various time frames [1] - As of May 23, 2025, the latest net value of the fund is 1.2814 yuan, reflecting a decrease of 1.07% [1] - The fund's one-month return is 5.81%, ranking 28 out of 1022 in its category, while the six-month return is 22.29%, ranking 32 out of 984, and the year-to-date return is 23.24%, ranking 30 out of 999 [1] Group 2 - The top ten holdings of the China Europe Medical Innovation Stock A fund account for a total of 75.62%, with the largest positions in WuXi AppTec (10.35%), Kelun-Biotech (10.15%), WuXi Biologics (9.82%), and WuXi AppTec (9.60%) [1] - The fund was established on February 28, 2019, and as of March 31, 2025, it has a total scale of 4.675 billion yuan [1] - The fund manager is Ms. Ge Lan, who has extensive experience in the investment management field, having joined China Europe Fund Management in October 2014 [2]

Core Viewpoint - The CRO (Contract Research Organization) sector has shown a positive performance with a 1.51% increase, ranking second among concept sectors, driven by significant gains in specific stocks like New Tian Di, which hit a 20% limit up [1][2]. Sector Performance - The CRO concept sector saw 42 stocks rise, with New Tian Di leading at a 20% increase, followed by Yang Guang Nuo He at 12.55%, Rui Zhi Yi Yao at 8.05%, and Hong Bo Yi Yao at 7.73% [1][2]. - Conversely, stocks like *ST Shuang Cheng, Si Chuan Shuang Ma, and Jin An Dan Bai experienced declines of 5.01%, 3.73%, and 3.19% respectively [1][2]. Capital Flow - The CRO sector experienced a net outflow of 507,500 yuan, with 29 stocks receiving net inflows. New Tian Di topped the list with a net inflow of 86,619,800 yuan, followed by Kang Long Hua Cheng with 58,064,600 yuan and Tai Ge Yi Yao with 49,707,000 yuan [2][3]. - The net inflow ratios for leading stocks included New Tian Di at 10.25%, Nuo Si Ge at 9.53%, and Kang Long Hua Cheng at 6.78% [3]. Stock Highlights - Key stocks in the CRO sector included: - New Tian Di: 20.02% increase, 57.74% turnover rate, net inflow of 86,619,800 yuan, net inflow ratio of 10.25% [3][4]. - Kang Long Hua Cheng: 2.38% increase, 2.58% turnover rate, net inflow of 58,064,600 yuan, net inflow ratio of 6.78% [3][4]. - Tai Ge Yi Yao: 5.64% increase, 4.82% turnover rate, net inflow of 49,707,000 yuan, net inflow ratio of 3.80% [3][4]. Declining Stocks - Notable declines included: - *ST Shuang Cheng: 5.01% decrease, with a significant net outflow of 1,391,440 yuan [5][6]. - Si Chuan Shuang Ma: 3.73% decrease, with a net outflow of 500,800 yuan [5][6]. - Jin An Dan Bai: 3.19% decrease, with a net outflow of 233,620 yuan [5][6].

Core Viewpoint - In Q1 2025, China's Corporate Venture Capital (CVC) sector experienced a significant decline in both the number of newly registered funds and the total fund size, indicating a challenging investment environment [2][3]. Fund Overview - In Q1 2025, 43 new CVC funds were registered, representing a year-on-year decrease of 35.82% and a quarter-on-quarter decrease of 30.65%. The total fund size was 17.988 billion yuan, down 72.03% year-on-year and 53.57% quarter-on-quarter [3]. - The majority of new funds were concentrated in Zhejiang and Guangdong, with Zhejiang leading with 12 funds, accounting for 27.91% of the total [5]. Investment Overview - A total of 125 CVCs participated in 175 investment events in Q1 2025, marking a year-on-year decline of 55.47% and a quarter-on-quarter decline of 20.81%. The disclosed total financing amount was 24.385 billion yuan, down 56.37% year-on-year and 69.73% quarter-on-quarter [7]. - The most active sectors for CVC investments were artificial intelligence and smart manufacturing, each with 46 financing events, followed by healthcare, materials, and enterprise services [9]. Regional Investment Focus - CVC investments were heavily concentrated in five regions: Guangdong, Jiangsu, Beijing, Shanghai, and Zhejiang, which accounted for 80.23% of all financing events [11]. Participation in Large Financing Events - CVCs participated in 5 large financing events (each over 100 million USD), representing 16.67% of the total large financing events in the primary investment market, the lowest proportion since 2024 [13]. - The sectors involved in these large financing events included artificial intelligence, enterprise services, smart manufacturing, materials, and blockchain [14]. IPO Participation - In Q1 2025, 64 Chinese companies completed IPOs, with 16 of them supported by CVCs, resulting in a CVC penetration rate of 25.4% [17]. - Notable IPOs included Mixue Ice City, which had a market value of nearly 150 billion yuan at the end of Q1 [18]. M&A Activity - CVCs were involved in 38 M&A events as buyers, with the healthcare sector leading with 7 events, followed by energy and enterprise services [19]. - As sellers, CVCs participated in 27 M&A events, with the energy sector also leading in terms of transaction value, totaling 634.67 billion yuan [21].

Group 1 - The overall market experienced a decline in the afternoon, but the pharmaceutical and medical sectors showed resilience, with only three out of 31 industries reporting gains [1] - The representative medical ETF (512170) saw a daily increase of 0.62%, with a significant trading volume of 9.82 billion, marking a 128% increase from the previous day and the highest single-day trading volume in over a month and a half [2] - The CXO-related stocks were the main contributors to the sector's performance, with notable gains from companies like Tigermed, which rose by 5.64%, while major player WuXi AppTec experienced a decline [2] Group 2 - For the week of May 19-23, the medical ETF (512170) accumulated a gain of 1.24%, outperforming major indices such as the Shanghai Composite Index, which fell by 0.57% [4] - The market for medical stocks is gradually recovering, with increased trading activity and positive catalysts such as domestic pharmaceutical companies securing overseas contracts [4] - A new "Pharmaceutical ETF" is set to launch on May 26, which will track the CSI Pharmaceutical Index, focusing on chemical drugs, biological drugs, and traditional Chinese medicine, complementing the existing medical ETF [4] Group 3 - The medical and pharmaceutical sectors have been in a prolonged adjustment period since 2021, with current valuations potentially offering high cost-effectiveness for investors [4]

每经记者｜曾子建 每经编辑｜叶峰 本周，A股市场震荡回落。尤其是周五，沪指跌近1%，报收于3348.37点，周跌幅为0.57%。 ETF方面，超过半数产品本周未能实现正收益，但港股创新药板块逆势走强，多只产品创出历史新高。 从成分股看，港股市场上的康哲药业、昭衍新药、泰格医药等，本周都有较大涨幅。消息面上，近期多家创新药企宣布将在本月底的ASCO（美国临床肿瘤 学会）大会上披露多项旗下创新管线的重磅临床和研发数据，有望成为整个创新药产业的短期最强催化剂。据了解，ASCO是全球肿瘤学领域规模最大、最 具影响力的学术盛会之一。 券商机构认为，5月份开始，市场将进入业绩真空期，投资关注点由业绩转变为行业和公司基本面变化。目前我国创新药进入成果兑现阶段，研发进展催化 较多，且不受对等关税影响，有望持续成为2025年医药板块的投资主线。 除了港股创新药板块外，黄金股相关ETF在本周也有不错表现。其中，多只黄金股ETF本周涨幅超过6%。 跌幅榜：一周下跌4%，金融科技ETF跌幅居前 本周，市场风格对科技领域突然变得不那么友好，金融科技、人工智能、机器人、计算机相关产品均表现不佳。 涨幅榜：两类产品表现强势，港股创新药领涨 ...

Market Performance - The Hong Kong stock market showed mixed results with the Hang Seng Index up by 0.24%, the Hang Seng China Enterprises Index up by 0.31%, and the Hang Seng Tech Index down by 0.09% [1] Sector Highlights - The film sector saw significant gains, with Alibaba Pictures (01060.HK) rising by 8.45% and a total increase of 63.83% over the past four trading days. Citi noted that the potential of its IP products has not been fully realized, with "Chiikawa" and "Crayon Shin-chan" expected to contribute in FY2026 [1] - Solar energy stocks also performed well, with Fuyao Glass (03606.HK) up by 4.64% and Rainbow New Energy (00438.HK) up by 2.5%. Additionally, some nuclear power stocks saw notable increases, such as CGN Mining (01164.HK) up by 8.5% and CGN Power (01816.HK) up by 1.72% [1] - The automotive supply chain, including Tesla-related stocks and lithium battery companies, experienced upward movement. Nexperia (01316.HK) rose by 4.4%, Yongda Auto (03669.HK) by 2.37%, Brilliance China (01114.HK) by 3.13%, and Great Wall Motors (02333.HK) by 2.42%. According to the China Passenger Car Association, the retail market for narrow passenger cars is expected to reach approximately 1.85 million units this month, representing a year-on-year increase of 8.5% and a month-on-month increase of 5.4% [1] Active Stocks - The pharmaceutical outsourcing sector was active, with Tigermed (03347.HK) up by 8.35%, Zai Lab (06127.HK) up by 7.34%, and other related companies also showing gains. Institutions noted a fundamental turning point in the CXO sector, with continued growth expected in small molecule and large molecule CDMO orders [2] - Other sectors with notable gains included pork, agriculture, tobacco, and beer [3] Declining Stocks - The luxury goods, Hong Kong retail, dairy, department store, food, and airline sectors faced declines, with stocks like Eslon (01856.HK) down by 5.43% and China Wangwang (00151.HK) down by 2.11% [3] - SaaS stocks generally underperformed, with Huizhongda Network (09878.HK) down by 9.22% and other related companies also declining [3] - Apple-related stocks experienced pullbacks, including Q Technology (01478.HK) down by 3.06% and GoerTek (01415.HK) down by 2.88% [3] Other Notable Movements - Cement stocks and property management stocks showed poor performance, while education and semiconductor stocks also weakened [4] - Specific cement companies like China National Building Material (00691.HK) fell by 6.6% [5] - Heng Rui Pharmaceutical (01276.HK) saw a significant increase of 25.2% on its first day of trading [6] - FIH Mobile (02981.HK) rose by 22.62% after being included in the Hong Kong Stock Connect following a share consolidation [7]

消息面上，在创新治疗领域，中国企业的国际合作一直在持续。此前，百利天恒将双抗AD授权给百时 美施贵宝，以84亿美元的金额刷新了中国ADC新药"出海"的交易金额纪录。而刚实现"A+H"两地上市的 恒瑞医药近年来的BD更是进展迅速。截至目前，恒瑞医药已经实现14笔创新药License-out（对外授 权），其中近三年对外授权9笔，合作方包括默克、默沙东等国际巨头，涉及GLP-1、ADC等热门领 域。2024年中国创新药对License-out完成94笔，出海交易总金额高达519亿美元，同比增长26%。 大而全：创新药ETF（159992）跟踪创新药指数，该指数布局创新药产业链龙头企业，既汇聚全球CXO 龙头企业，又包含国内仿创药企龙头，有望同时受益于AI赋能创新药、国产创新药出海、针对高价创 新药的医保丙类目录出台等。 中信建投证券认为，创新药板块近年来展现出强劲的技术驱动发展势头，尤其在抗体偶联药物 （ADC）、双特异性抗体（双抗）以及小分子疗法等领域取得了显著进展。以2025年美国临床肿瘤学 会（ASCO）年会为例，中国创新药企在此次会议上提交了超过70项口头报告，其中Late Breaking Abstra ...

Group 1 - The A-share market has returned to levels seen before April 2, indicating an upward adjustment in economic expectations for the second quarter, which may enhance risk appetite [1] - The market is expected to focus on structural trends, with a potential rotation between dividend and technology sectors contributing to excess returns [1] - The A500 index, designed with an "industry balance" approach, provides a natural barbell structure by evenly distributing investments between dividend and technology sectors [1] Group 2 - The A500 ETF (159339) has shown a high market activity with an average daily trading volume of 261 million yuan over the past 20 trading days [1] - In the A500 index, stocks such as Betta Pharmaceuticals and Sihuan Pharmaceutical have risen over 9%, while Huahai Pharmaceutical and Tigermed have increased over 7% [1] - The A50 ETF (159592) tracks the A50 index, which focuses on large-cap leading stocks across various industries, benefiting from increased market concentration due to supply-side reforms [2] Group 3 - Recent trade negotiations have led to a temporary recovery in market sentiment, but subsequent pullbacks indicate a return to rationality among investors, focusing more on fundamental support [2] - The previous rise in A-shares was primarily driven by event-based sentiment rather than substantial improvements in corporate earnings or macroeconomic conditions [2] - As short-term sentiment factors fade, capital pricing is expected to align more closely with actual business performance and industry development trends [2]

Group 1 - The core viewpoint highlights the active trading and positive performance of the China A500 ETF Morgan and A500 Enhanced ETF Morgan, with the CSI A500 Index showing a slight increase of 0.14% as of 13:36 on May 23, 2025 [1] - Notable stocks within the CSI A500 Index include Siasun (601127) reaching a daily limit increase, Betta Pharmaceuticals (300558) rising by 12.02%, Huahai Pharmaceutical (600521) increasing by 8.47%, Tigermed (300347) up by 7.92%, and Xinlitai (002294) gaining 5.65% [1] Group 2 - Institutions emphasize the increasing asset allocation value in China, with "Opportunities in China amid Global Changes" becoming a significant topic in mid-term strategy outlooks [3] - The Chinese economy is showing steady improvement, supported by a combination of market stabilization policies that inject more certainty into the capital market, enhancing the attractiveness of Chinese assets [3] - Brokerages generally view Chinese assets as having both risk-hedging properties and long-term allocation value, positioning them as a "safe haven" for global funds [3] - Morgan Asset Management is focused on identifying relatively "certain" quality asset investment opportunities, launching the international "Dividend Toolbox" series of preferred funds to provide diversified dividend investment solutions for Chinese investors covering A-shares, Hong Kong stocks, and Asian markets [3]

Group 1 - The liquidity of the ChiNext 50 ETF managed by Harvest has a turnover rate of 4.06% with a trading volume of 15.6495 million yuan, and the average daily trading volume over the past year is 35.3545 million yuan [3] - The fund has seen a significant increase in shares, with a growth of 19.5 million shares in the past three months, ranking among the top two in comparable funds [3] - The valuation of the ChiNext 50 Index is at a historical low, with the latest price-to-book ratio (PB) at 4.27 times, which is lower than 80.56% of the time over the past five years, indicating a strong value proposition [3] Group 2 - The pharmaceutical and biotechnology industry is expected to gradually recover in 2025 after a low period in 2024, which will stabilize the growth hormone sector [4] - In the medical device sector, there is a clear trend of replacement, with significant market potential in sub-segments like endoscopy and micro-electrophysiology, where domestic production rates are low [4] - The industry is benefiting from accelerated aging, improved medical insurance payment systems, and the application of AI technology, with innovative drugs and high-barrier fields such as blood products and anesthetics becoming the main development lines [4]